The present disclosure provides biomarkers useful as companion diagnostics for detecting glycocalyx-based disease that is amenable to treatment using compounds designed for improving the condition of the glycocalyx and/or reducing inflammation and/or oxidative damage, as well as related compositions, kits, and methods.

The present disclosure provides biomarkers useful as companion diagnostics for detecting glycocalyx-based disease that is amenable to treatment using compounds designed for improving the condition of the glycocalyx and/or reducing inflammation and/or oxidative damage, as well as related compositions, kits, and methods.

Embodiments of this invention provide compounds, compositions, methods, and uses for therapeutic diketopiperazines, including cyclic G-2-Allyl Proline and other cyclic Glycyl Proline compounds to treat Pitt Hopkins Syndrome and symptoms thereof, as well as manufacture of compositions, medicaments including tablets, capsules, liquid formulations, gels, injectable solutions, and other formulations that are useful for treatment of such conditions.

Embodiments of this invention provide compounds, compositions, methods, and uses for therapeutic diketopiperazines, including cyclic G-2-Allyl Proline and other cyclic Glycyl Proline compounds to treat Pitt Hopkins Syndrome and symptoms thereof, as well as manufacture of compositions, medicaments including tablets, capsules, liquid formulations, gels, injectable solutions, and other formulations that are useful for treatment of such conditions.

The present invention provides a novel use and methods comprising antibodies, or antigen-binding fragments thereof, which bind to a CCR7 receptor for use as a novel combination therapy with a BTK inhibitor and/or a Bcl-2 inhibitor in treatment of hyperproliferative blood malignancies, preferably in B-cell lymphomas, such as CLL. The combination can be used as first line, or in naïve patients not treated before with a BTK inhibitor and/or Bcl-2 inhibitor, or in patients with a BTK-inhibitor and/or Bcl-2-inhibitor refractory/relapsed disease. The antibodies and antigen-binding fragments are capable of selectively depleting ex vivo or in vitro malignant cells expressing CCR7 and are capable of impairing/blocking migration of said tumor cells towards CCR7 ligands. These effects are not related to previous or contemporary treatments with a BTK inhibitor and/or a Bcl-2 inhibitor. Similarly, the efficacy of the antibodies is not affected in patients that have relapsed/refractory disease. The use of said antibodies as a monotherapy or as a combination with a BTK inhibitor and/or a Bcl-2 inhibitor for depleting, killing and impairing/blocking migration and activation of tumor cells expressing CCR7 cells is disclosed, thus providing an alternative therapy treating hyperproliferative blood cancers.

The present invention provides a novel use and methods comprising antibodies, or antigen-binding fragments thereof, which bind to a CCR7 receptor for use as a novel combination therapy with a BTK inhibitor and/or a Bcl-2 inhibitor in treatment of hyperproliferative blood malignancies, preferably in B-cell lymphomas, such as CLL. The combination can be used as first line, or in naïve patients not treated before with a BTK inhibitor and/or Bcl-2 inhibitor, or in patients with a BTK-inhibitor and/or Bcl-2-inhibitor refractory/relapsed disease. The antibodies and antigen-binding fragments are capable of selectively depleting ex vivo or in vitro malignant cells expressing CCR7 and are capable of impairing/blocking migration of said tumor cells towards CCR7 ligands. These effects are not related to previous or contemporary treatments with a BTK inhibitor and/or a Bcl-2 inhibitor. Similarly, the efficacy of the antibodies is not affected in patients that have relapsed/refractory disease. The use of said antibodies as a monotherapy or as a combination with a BTK inhibitor and/or a Bcl-2 inhibitor for depleting, killing and impairing/blocking migration and activation of tumor cells expressing CCR7 cells is disclosed, thus providing an alternative therapy treating hyperproliferative blood cancers.

The present invention provides a BET (protein) degrader, specifically a BET degrader containing a compound represented by formula (I) or a pharmaceutically acceptable salt thereof:

##STR00001##

wherein L1 and L2 are the same or different and each represents a small molecular ligand for BET protein, and S represents a group represented by a formula selected from the group consisting of formulas (S1) to (S18).

The object of the present invention is to potentiate the photodynamic effect in ALA-PDT and ALA-PDD. The present invention provides a pharmaceutical related to a combination of ALAs and a dynamin inhibitor.

The object of the present invention is to potentiate the photodynamic effect in ALA-PDT and ALA-PDD. The present invention provides a pharmaceutical related to a combination of ALAs and a dynamin inhibitor.

The object of the present invention is to potentiate the photodynamic effect in ALA-PDT and ALA-PDD. The present invention provides a pharmaceutical related to a combination of ALAs and a dynamin inhibitor.